Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2026

Nyxoah reported preliminary Q2 2026 net revenue of ~€7.7m worldwide (+21% sequential), including ~€5.2m in the U.S. (+22% sequential), with active high-volume accounts rising to 180 (up from 89 new activations in the quarter). The company also said CMS has proposed hospital reimbursement for the Genio procedure (C8011) to increase from $31,526 to $35,414 (+$3,888, +12%) and ASC reimbursement to rise from $27,563 to $31,722 (+$4,159, +15%), supporting the economics if approved. Nyxoah secured $110m of total financing in Q2 and expects full-year 2026 net revenue of €36m–€40m, moving the stock sentiment modestly higher but remaining dependent on reimbursement approval.

Analysis

The main economic signal is not the revenue print itself but the combination of reimbursement uplift and a still-early commercial footprint: if the proposed CMS rates hold, Nyxoah should see a better conversion rate from trained surgeons to realized implants because hospitals and ASCs have less reason to reject the economics. That matters most over the next 1-3 quarters, when prior-auth submissions are the leading indicator; the bottleneck is now operational execution, not lack of payer rationale.

Second-order, the benefit is broader than NYXH. Any positive reimbursement step for HGNS expands the category and lowers hesitation for the larger installed players, especially Inspire Medical Systems, but NYXH has the sharper operating leverage because each incremental implant is a larger share of its base. The flip side is that reimbursement does not equal demand: if physician adoption, anesthesia capacity, or patient conversion stalls, the incremental CMS dollars simply improve site economics without translating into proportional top-line acceleration.

The contrarian read is that the market may overestimate how quickly proposed rates become realized cash flow. Final CMS rule timing, local coverage behavior, and coding friction are the key falsifiers; a delay into late 2026 would push the valuation catalyst out by quarters. Over 6-18 months, the real debate is whether NYXH can use this window to become self-funding before the balance-sheet premium fades; if US revenue decelerates below 15-20% sequential growth or active accounts stop expanding, the thesis weakens materially.

Key Decisions for Investors

• Tactically long NYXH into the July 8 investor day, but only as a 4-8 week event-driven position; upside is tied to management quantifying conversion from prior-auth pipeline to implant revenue, while the main risk is a 'good story, slow monetization' gap-down.
• Use NYXH Jan-2027 call spreads instead of stock if liquidity allows: risk/reward is attractive if CMS reimbursement is finalized and US growth stays above 20% sequentially, but the structure limits damage if the rule slips or adoption plateaus.
• Pair trade: long NYXH / short INSP for relative upside if the market underestimates NYXH's incremental leverage from reimbursement expansion; this works only if NYXH proves its sales-force build can translate into a higher conversion rate than the category leader's already-embedded base.
• No direct trade in CMS from this release; treat it as a watch item for the final OPPS/ASC rule. Falsifier for the NYXH bullish case: CMS final rates materially below proposal, or Q3 revenue growth falling back below low-double-digit sequential growth despite the expanded surgeon/account base.
• If NYXH trades up sharply on the headline, fade strength after the investor day unless management can show accelerating account productivity; the trade is likely to be better on pullbacks than chasing the first move.